Servicio de Información Comunitario sobre Investigación y Desarrollo - CORDIS

FP6

MILD-TB Informe resumido

Project ID: 37326
Financiado con arreglo a: FP6-LIFESCIHEALTH
País: Italy

Final Report Summary - MILD-TB (Immunogenicity of Mycobacterium tuberculosis lipids in the non replicating status of latency)

Tuberculosis is a disease in which traditional prophylactic approaches have been largely unsuccessful. The search for new therapeutic interventions is required to overcome the low compliance to complex chemo-antibiotic regimens and to avoid multi-drug resistance. The aim of this project was to produce new knowledge and insight that bear a potential for new therapeutic or prophylactic interventions focusing on one of the most critical immune evasion mechanism of Mycobacterium tuberculosis (Mtb): the capacity to switch to a dormant status of latency, which causes its persistence in the host.

The switch implies a reduction/abrogation of the synthesis of antigens required for activation of T lymphocytes primed in the early phase of infection, while new products are generated with possible antigenic properties. MILD-TB analysed the variations in lipid metabolism and composition associated to dormancy. This represents an advancement beyond the current state of knowledge which was limited to proteins synthesised during dormancy.

The project has analysed the immunogenicity of lipids isolated from non-replicating Mtb produced in vitro using a culture method resembling Mtb dormancy in vivo. Lipids have been analysed in reference strains and clinical isolates from endemic areas and compared with those produced by replicating Mtb. The immunogenicity of lipids specifically isolated from dormant Mtb has been determined using pre-existing and newly established lipid-specific T cell clones and by immunising CD1b transgenic mice.

Parallel analysis of susceptibility of dormant Mtb to T-dependent mechanisms of direct or indirect killing have been performed to explore the possibility of new therapeutic or prophylactic interventions based on vaccination with lipid-antigens or on immune modulation.

Información relacionada

Contacto

Roberto NISINI, (Senior Researcher)
Tel.: +39-06-49902659
Fax: +39-06-49387112
Correo electrónico
Síganos en: RSS Facebook Twitter YouTube Gestionado por la Oficina de Publicaciones de la UE Arriba